中文名:Vortioxetine (Lu AA21004) HBr
英文名:Vortioxetine (Lu AA21004) HBr
英文別名:Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-, hydrobromide (1:1)
純度:10mM in DMSO
貨號:V409169
包裝:1ml
Cas號:960203-27-4
存儲溫度:-80℃儲存
產(chǎn)品介紹:
Information
Vortioxetine (Lu AA21004), a multimodal serotonergic agent, is an antagonist ofhuman (h) serotonin (5-HT)3A receptorandh5-HT7 receptorwith Ki of 3.7 nM and 19 nM, respectively. Vortioxetine (Lu AA21004) is also ah5-HT1B receptorpartial agonist with Ki of
In?vitro
Lu-AA21004 inhibits recombinant human CYP1A2, CYP2C9, CYP2D6 and CYP3A4 with IC50 of 40 μM, 39 μM, 9.8 μM and 10 μM, respectively. Lu AA21004 is a partial h5-HT1B receptor agonist with EC50 of 460 nM and intrinsic activity of 22% using a whole-cell cAMP-based assay. Lu AA21004 binds to the r5-HT7 receptor with a Ki value of 200 nM and is a functional antagonist at the r5-HT7 receptor with an IC50 of 2 μM in an in vitro whole-cell cAMP assay.
In?vivo
For Lu-AA21004 the hepatic clearances and oral bioavailabilities in rats are found to be 7.1 (L/h)/kg and 16%. Lu-AA21004 (2.5 mg/kg, 5 mg/kg, or 10 mg/kg sc) increases the extracellular levels of 5-HT in the ventral hippocampus in conscious rats. Lu-AA21004 (5 mg/kg, or 10 mg/kg sc) also results in significantly higher basal levels of 5-HT in the medial prefrontal cortex (mPFC) after 3 days of treatment. Lu-AA21004 occupies SERT by 43% and 57% after 3 days of treatment with 5 mg/kg or 10 mg/kg in the rat medial prefrontal cortex. Lu AA21004 dose-dependent occupies 5-HT1B receptor and the SERT with ED50 of 3.2 mg/kg and 0.4 mg/kg in rats one hour after subcutaneous administration. Lu AA21004 affects the Bezold-Jarisch reflex in the rat dose dependently, inhibiting transient bradycardia with ED50 of 0.11 mg/kg. Lu AA21004 (2.5-10.0 mg/kg s.c.) increases extracellular levels of 5-HT, DA, and NA in the medial prefrontal cortex and in the ventral hippocampus in rats. Lu AA21004 (5 mg/kg s.c.) increases in the extracellular levels of 5-HT (200%) in the ventral hippocampus of rats with 41% occupancy at the SERT. Lu AA21004 (7.8 mg/kg s.c.) significantly decreases the immobility time in the FSL rats but not in the FRL rats. Lu AA21004 (8.0 mg/kg p.o.) produces an increase in social interaction as well as a small, but significant, increase in locomotor activity in rats. Lu AA21004 (7.9 mg/kg s.c.) shows a dose-dependent anxiolytic-like effect in the conditioned fear assay in rats. Vortioxetine (10 mg/kg) significantly increases freezing 60 min before acquisition in male Sprague-Dawley rats, suggesting enhanced contextual memory formation during acquisition and/or consolidation. Vortioxetine (5 mg/kg) also causes increased freezing rates during retention, an effect that reached statistical significance by post hoc tests. Vortioxetine (2.5 mg/kg or 5 mg/kg) prior to acquisition shows average exploration times of 29s and 33s for the novel object, respectively. Vortioxetine (10 mg/kg) significantly reduces nociception in rats, assessed as increased paw withdrawal latency. Vortioxetine at 5 and 10 mg/kg increases the levels of ACh to 224% and 204% of baseline 20 min after injection.
Cell?Data
cell?lines:HEK293 cells
Concentrations:
Incubation?Time:
Powder?Purity:≥99%
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應(yīng)頁面:https://www.aladdin-e.com/zh_cn/V409169.html
關(guān)鍵字: Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-, hydrobromide (1:1)
上海阿拉丁生化科技股份有限公司是A股上市公司((股票代碼:688179),專注于科研試劑的研發(fā)、生產(chǎn)和銷售,已陸續(xù)建立多個工廠和研發(fā)中心。作為領(lǐng)軍企業(yè),阿拉丁始終堅持質(zhì)量第一,連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產(chǎn)品品種超過7萬種,SKU總數(shù)超過46萬,產(chǎn)品線涵蓋了化學(xué)試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個領(lǐng)域,是國內(nèi)少數(shù)化學(xué)試劑到生物試劑全面發(fā)展的國產(chǎn)試劑品牌,產(chǎn)品同步發(fā)布在我們國內(nèi)外電商平臺。